For the year ending 2025-12-31, AVNS had -$17,900K decrease in cash & cash equivalents over the period. $43,100K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -72,900 |
| Depreciation and amortization | 38,900 |
| Stock-based compensation | 12,600 |
| Goodwill and intangibles impairment | 77,000 |
| Loss on rh disposal | 0 |
| Net losses on asset dispositions and asset impairments | -9,300 |
| Accounts receivable | -30,900 |
| Inventories, net of allowance | -200 |
| Prepaid expenses and other assets | -1,400 |
| Accounts payable | 600 |
| Accrued expenses | -12,900 |
| Deferred income taxes and other | -10,400 |
| Cash provided by operating activities | 74,700 |
| Capital expenditures | 31,600 |
| Proceeds from the sale of assets | 4,000 |
| Proceeds from the rh divestiture | 0 |
| Proceeds from rh divestiture post-closing settlement | 0 |
| Acquisition of assets and businesses, net of cash acquired | 28,000 |
| Investments in non-affiliates | 5,000 |
| Cash (used in) provided by investing activities | -60,600 |
| Secured debt repayments | 9,400 |
| Revolving credit facility proceeds | 0 |
| Revolving credit facility repayments | 25,000 |
| Purchase of treasury stock | 3,300 |
| Proceeds from the exercise of stock options | 700 |
| Payment of contingent consideration liabilities | 0 |
| Cash used in financing activities | -37,000 |
| Effect of exchange rate changes on cash and cash equivalents | 5,000 |
| (decrease) increase in cash and cash equivalents | -17,900 |
| Cash and cash equivalents - beginning of year | 107,700 |
| Cash and cash equivalents - end of year | 89,800 |
AVANOS MEDICAL, INC. (AVNS)
AVANOS MEDICAL, INC. (AVNS)